Latiglutenase - Entero Therapeutics
Alternative Names: ALV-003; IMGX 001; IMGX 002; IMGX-003; IMGX001 + IMGX002Latest Information Update: 12 Aug 2024
At a glance
- Originator Stanford University
- Developer Entero Therapeutics
- Class Cysteine endopeptidases; Enzymes; Recombinant proteins
- Mechanism of Action Gluten modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Coeliac disease
Most Recent Events
- 01 Aug 2024 Entero Therapeutics terminates a phase II trial for Coeliac disease in USA due to low enrollment related to Covid (PO) (NCT04243551)
- 31 Jul 2024 Entero Therapeutics intends to submit two Type D meeting requests to the FDA to develop a more precise and efficient Phase III clinical trial design and development plan for Latiglutenase
- 16 May 2024 First Wave Biopharma is now called Entero Therapeutics